The Utilization of Gleason Grade as the Primary Criterion for Ordering Nuclear Bone Scan in Newly Diagnosed Prostate Cancer Patients

Utilization of nuclear bone scans for staging newly diagnosed prostate cancer has decreased dramatically due to PSA-driven stage migration. The current criteria for performing bone scans are based on limited historical data. This study evaluates serum PSA and Gleason grade in predicting positive sca...

Full description

Saved in:
Bibliographic Details
Main Authors: Chad W. M. Ritenour, John T. Abbott, Michael Goodman, Naomi Alazraki, Fray F. Marshall, Muta M. Issa
Format: Article
Language:English
Published: Wiley 2009-01-01
Series:The Scientific World Journal
Online Access:http://dx.doi.org/10.1100/tsw.2009.113
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841524441285132288
author Chad W. M. Ritenour
John T. Abbott
Michael Goodman
Naomi Alazraki
Fray F. Marshall
Muta M. Issa
author_facet Chad W. M. Ritenour
John T. Abbott
Michael Goodman
Naomi Alazraki
Fray F. Marshall
Muta M. Issa
author_sort Chad W. M. Ritenour
collection DOAJ
description Utilization of nuclear bone scans for staging newly diagnosed prostate cancer has decreased dramatically due to PSA-driven stage migration. The current criteria for performing bone scans are based on limited historical data. This study evaluates serum PSA and Gleason grade in predicting positive scans in a contemporary large series of newly diagnosed prostate cancer patients. Eight hundred consecutive cases of newly diagnosed prostate cancer over a 64-month period underwent a staging nuclear scan. All subjects had histologically confirmed cancer. The relationship between PSA, Gleason grade, and bone scan was examined by calculating series of crude, stratified, and adjusted odds ratios with corresponding 95% confidence intervals. Four percent (32/800) of all bone scans were positive. This proportion was significantly lower in patients with Gleason score ≤7 (1.9%) vs. Gleason score ≥8 (18.8%, p < 0.001). Among patients with Gleason score ≤7, the rate of positive bones scans was 70-fold higher when the PSA was >30 ng/ml compared to ≤30 ng/ml (p < 0.001). For Gleason score ≥8, the rate was significantly higher (27.9 vs. 0%) when PSA was >10 ng/ml compared to ≤10 ng/ml (p = 0.002). The combination of Gleason score and PSA enhances predictability of bone scans in newly diagnosed prostate cancer patients. The PSA threshold for ordering bone scans should be adjusted according to Gleason score. For patients with Gleason scores ≤7, we recommend a bone scan if the PSA is >30 ng/ml. However, for patients with a high Gleason score (8–10), we recommend a bone scan if the PSA is >10 ng/ml.
format Article
id doaj-art-2601b4c8e4ca4d1dbd0e1b579397c0d9
institution Kabale University
issn 1537-744X
language English
publishDate 2009-01-01
publisher Wiley
record_format Article
series The Scientific World Journal
spelling doaj-art-2601b4c8e4ca4d1dbd0e1b579397c0d92025-02-03T05:53:07ZengWileyThe Scientific World Journal1537-744X2009-01-0191040104510.1100/tsw.2009.113The Utilization of Gleason Grade as the Primary Criterion for Ordering Nuclear Bone Scan in Newly Diagnosed Prostate Cancer PatientsChad W. M. Ritenour0John T. Abbott1Michael Goodman2Naomi Alazraki3Fray F. Marshall4Muta M. Issa5Department of Urology, Emory University, School of Medicine, Atlanta, GA, United StatesDepartment of Urology, Emory University, School of Medicine, Atlanta, GA, United StatesDeparment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United StatesDivision of Nuclear Medicine, Veterans Affairs Medical Center, Atlanta, GA, USADepartment of Urology, Emory University, School of Medicine, Atlanta, GA, United StatesDepartment of Urology, Emory University, School of Medicine, Atlanta, GA, United StatesUtilization of nuclear bone scans for staging newly diagnosed prostate cancer has decreased dramatically due to PSA-driven stage migration. The current criteria for performing bone scans are based on limited historical data. This study evaluates serum PSA and Gleason grade in predicting positive scans in a contemporary large series of newly diagnosed prostate cancer patients. Eight hundred consecutive cases of newly diagnosed prostate cancer over a 64-month period underwent a staging nuclear scan. All subjects had histologically confirmed cancer. The relationship between PSA, Gleason grade, and bone scan was examined by calculating series of crude, stratified, and adjusted odds ratios with corresponding 95% confidence intervals. Four percent (32/800) of all bone scans were positive. This proportion was significantly lower in patients with Gleason score ≤7 (1.9%) vs. Gleason score ≥8 (18.8%, p < 0.001). Among patients with Gleason score ≤7, the rate of positive bones scans was 70-fold higher when the PSA was >30 ng/ml compared to ≤30 ng/ml (p < 0.001). For Gleason score ≥8, the rate was significantly higher (27.9 vs. 0%) when PSA was >10 ng/ml compared to ≤10 ng/ml (p = 0.002). The combination of Gleason score and PSA enhances predictability of bone scans in newly diagnosed prostate cancer patients. The PSA threshold for ordering bone scans should be adjusted according to Gleason score. For patients with Gleason scores ≤7, we recommend a bone scan if the PSA is >30 ng/ml. However, for patients with a high Gleason score (8–10), we recommend a bone scan if the PSA is >10 ng/ml.http://dx.doi.org/10.1100/tsw.2009.113
spellingShingle Chad W. M. Ritenour
John T. Abbott
Michael Goodman
Naomi Alazraki
Fray F. Marshall
Muta M. Issa
The Utilization of Gleason Grade as the Primary Criterion for Ordering Nuclear Bone Scan in Newly Diagnosed Prostate Cancer Patients
The Scientific World Journal
title The Utilization of Gleason Grade as the Primary Criterion for Ordering Nuclear Bone Scan in Newly Diagnosed Prostate Cancer Patients
title_full The Utilization of Gleason Grade as the Primary Criterion for Ordering Nuclear Bone Scan in Newly Diagnosed Prostate Cancer Patients
title_fullStr The Utilization of Gleason Grade as the Primary Criterion for Ordering Nuclear Bone Scan in Newly Diagnosed Prostate Cancer Patients
title_full_unstemmed The Utilization of Gleason Grade as the Primary Criterion for Ordering Nuclear Bone Scan in Newly Diagnosed Prostate Cancer Patients
title_short The Utilization of Gleason Grade as the Primary Criterion for Ordering Nuclear Bone Scan in Newly Diagnosed Prostate Cancer Patients
title_sort utilization of gleason grade as the primary criterion for ordering nuclear bone scan in newly diagnosed prostate cancer patients
url http://dx.doi.org/10.1100/tsw.2009.113
work_keys_str_mv AT chadwmritenour theutilizationofgleasongradeastheprimarycriterionfororderingnuclearbonescaninnewlydiagnosedprostatecancerpatients
AT johntabbott theutilizationofgleasongradeastheprimarycriterionfororderingnuclearbonescaninnewlydiagnosedprostatecancerpatients
AT michaelgoodman theutilizationofgleasongradeastheprimarycriterionfororderingnuclearbonescaninnewlydiagnosedprostatecancerpatients
AT naomialazraki theutilizationofgleasongradeastheprimarycriterionfororderingnuclearbonescaninnewlydiagnosedprostatecancerpatients
AT frayfmarshall theutilizationofgleasongradeastheprimarycriterionfororderingnuclearbonescaninnewlydiagnosedprostatecancerpatients
AT mutamissa theutilizationofgleasongradeastheprimarycriterionfororderingnuclearbonescaninnewlydiagnosedprostatecancerpatients
AT chadwmritenour utilizationofgleasongradeastheprimarycriterionfororderingnuclearbonescaninnewlydiagnosedprostatecancerpatients
AT johntabbott utilizationofgleasongradeastheprimarycriterionfororderingnuclearbonescaninnewlydiagnosedprostatecancerpatients
AT michaelgoodman utilizationofgleasongradeastheprimarycriterionfororderingnuclearbonescaninnewlydiagnosedprostatecancerpatients
AT naomialazraki utilizationofgleasongradeastheprimarycriterionfororderingnuclearbonescaninnewlydiagnosedprostatecancerpatients
AT frayfmarshall utilizationofgleasongradeastheprimarycriterionfororderingnuclearbonescaninnewlydiagnosedprostatecancerpatients
AT mutamissa utilizationofgleasongradeastheprimarycriterionfororderingnuclearbonescaninnewlydiagnosedprostatecancerpatients